GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Total Receivables

HBM Holdings (HBM Holdings) Total Receivables : $63.72 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Total Receivables?

HBM Holdings's Total Receivables for the quarter that ended in Dec. 2023 was $63.72 Mil.


HBM Holdings Total Receivables Historical Data

The historical data trend for HBM Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Total Receivables Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial 1.99 2.12 1.31 26.34 63.72

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.31 18.11 26.34 22.06 63.72

HBM Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


HBM Holdings Total Receivables Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


HBM Holdings (HBM Holdings) Business Description

Traded in Other Exchanges
Address
420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire 01-19-2024